ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

U.S. Charges Bristol-Myers Executive With Insider Trading

By Peter Loftus Federal authorities arrested a Bristol-Myers Squibb Co. (BMY) executive Thursday on charges that he used inside information about the drug maker's acquisition targets to make more than $300,000 in illicit profits from stock-option trading. The U.S. Attorney's Office in New Jersey charged Robert Ramnarine, the drug maker's assistant treasurer for capital markets, with three counts of insider trading. Bristol-Myers issued a statement Thursday saying Mr. Ramnarine has been placed on administrative leave effective immediately. "Bristol-Myers Squibb has clear and strict policies prohibiting trading on material non-public information and is cooperating with the government's investigation," the company said. Mr. Ramnarine, of East Brunswick, N.J., allegedly purchased options in three companies that Bristol was targeting: ZymoGenetics Inc., Pharmasset Inc. and Amylin Pharmaceuticals Inc. (AMLN). Bristol-Myers purchased ZymoGenetics for $829 million in 2010 and agreed in June to acquire Amylin for $5.3 billion. Gilead Sciences Inc. (GILD) acquired Pharmasset for $11 billion earlier this year. Mr. Ramnarine served as director and executive director of pensions and savings investments at Bristol-Myers from 2008 until July 2012, when he was named to assistant treasurer of capital markets, according to a criminal complaint filed against Mr. Ramnarine in U.S. District Court in New Jersey. The complaint said Mr. Ramnarine was involved in evaluating potential Bristol-Myers acquisition targets in those roles, and had a duty not to use material, non-public information for his personal benefit. According to the complaint, Bristol-Myers began negotiating with ZymoGenetics about a deal in May 2010, and announced an agreement in September 2010. Before the public announcement, Mr. Ramnarine purchased ZymoGenetics call options, which he sold after the announcement for a profit of $30,551, according to the complaint. Bristol-Myers also explored a potential acquisition of Pharmasset in October and November of 2011 before withdrawing from discussions, which cleared the way for Gilead's acquisition, according to the complaint. Before the November announcement of the Gilead purchase of Pharmasset, Mr. Ramnarine purchased Pharmasset call options that eventually netted him about $225,026 in illicit profits, the complaint said. According to the complaint, Bristol-Myers made a preliminary offer to acquire Amylin for $25 to $27 per share in May, ultimately agreeing to pay $31 per share in June. Before the public announcement, Mr. Ramnarine purchased Amylin options that resulted in profits of $55,784, according to the complaint. Mr. Ramnarine is in custody and scheduled to make an initial court appearance in federal court in Newark, N.J., Thursday afternoon. A call to a phone listing for a Robert Ramnarine of East Brunswick, N.J., wasn't immediately returned. Write to Peter Loftus at Subscribe to WSJ:

Stock News for Gilead Sciences (GILD)
10/24/201617:00:00Gilead Sciences to Present at the Credit Suisse 25th Annual Healthcare...
10/24/201606:24:00Gilead Presents Results from Phase 3 Studies Evaluating Switching...
10/20/201610:07:00Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily...
10/20/201610:05:00Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib...
10/06/201612:30:00Singapore's Temasek Hires Veteran Goldman Banker
10/05/201612:54:17Statement of Changes in Beneficial Ownership (4)
10/04/201618:03:00FDA Warns on Hepatitis C Drugs
10/03/201619:53:39Statement of Changes in Beneficial Ownership (4)
09/27/201616:05:00Gilead Sciences and the World Health Organization Announce Five-Year...
09/26/201616:56:18Statement of Changes in Beneficial Ownership (4)
09/21/201619:05:00Gilead Sciences Halts Test of Bowel Disease Treatment
09/21/201617:00:00Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With...
09/20/201617:09:06Current Report Filing (8-k)
09/19/201616:47:49Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
09/16/201606:06:02Free Writing Prospectus - Filing Under Securities Act Rules 163/433...
09/15/201622:01:00Gilead Prices $5 Billion of Senior Unsecured Notes
09/15/201608:58:00Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
09/13/201610:25:57Confidential Treatment Order (ct Order)
09/13/201600:30:00Scientists Honored for Hep C Research
09/12/201611:18:49Confidential Treatment Order (ct Order)

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations